Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of IN-C005 in Healthy Males
NCT04485884Phase 1Unknown
- Sponsor
- HK inno.N Corporation
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IN-C005 in gastroesophageal reflux disease (GERD) and Helicobacter pylori infection (6 arms), sponsored by HK inno.N Corporation. Primary endpoints: Maximum Plasma Concentration up to 48 hours and Area Under the Curve up to 48 hours. Status: unknown.
02
Drugs
IN-C005
03
Conditions
gastroesophageal reflux disease (GERD)Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04485884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485884.